9 articles with Zai Lab
Qiming's portfolio company Zai Lab, an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited
9/24/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China
Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China
5/26/2020Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
Zai Lab Limited announced the China National Medical Products Administration has accepted its supplemental New Drug Application for ZEJULA® as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
2/10/2020Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.
1/13/2020The first full business week of the new year began with plenty of clinical trial news. Here’s a look.
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Zai Lab Limited and Novocure announced that the first patient has been enrolled in a phase 2 pilot clinical trial evaluating the safety and efficacy of Tumor Treating Fields in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma.